Pierluigi Porcu

TitleProfessor
InstitutionThomas Jefferson University
DepartmentMedical Oncology
Address925 Chestnut Street
Philadelphia PA 19107
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Johnson WT, Kartan S, Sokol K, Nikbakht N, Porcu P. Clinical characteristics and outcomes of black patients with mycosis fungoides and Sézary syndrome: a subgroup analysis of the phase III MAVORIC trial. Leuk Lymphoma. 2021 Feb 22; 1-8. PMID: 33618592.
      Citations:    
    2. Pan J, Ghimire S, Alpdogan SO, Chapman A, Carabasi M, DiMeglio M, Gong J, Martinez-Outschoorn U, Rose L, Ramirez M, Wagner JL, Weiss M, Flomenberg N, Pro B, Porcu P, Filicko-OHara J, Gaballa S. Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2020 Nov 04; 1-8. PMID: 33146052.
      Citations:    
    3. Hannon M, Porcu P, Gong JZ, Ackermann L. Relapsed Splenic Lymphoma Mimicking Recurrent Pyelonephritis. Am J Med. 2020 Sep 28. PMID: 33002495.
      Citations:    
    4. Porcu P, Hudgens S, Horwitz S, Quaglino P, Cowan R, Geskin L, Beylot-Barry M, Floden L, Bagot M, Tsianakas A, Moskowitz A, Huen A, Dreno B, Dalle S, Caballero D, Leoni M, Dale S, Herr F, Duvic M. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2020 Sep 18. PMID: 33158772.
      Citations:    
    5. Isidori A, de Leval L, Gergis U, Musto P, Porcu P. Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: Practical Considerations and Lessons to Be Learned. Front Oncol. 2020; 10:1439. PMID: 32923397.
      Citations:    
    6. Grosso D, Carabasi M, Filicko-O'Hara J, Wagner JL, O'Hara W, Sun M, Colombe B, Shi W, Werner-Wasik M, Rudolph S, Alpdogan O, Binder A, Kasner M, Klumpp T, Martinez-Outschoorn U, Palmisiano N, Wilde L, Porcu P, Gergis U, Flomenberg N. Low Nonrelapse Mortality after HLA-Matched Related 2-Step Hematopoietic Stem Cell Transplantation Using Cyclophosphamide for Graft-versus-Host Disease Prophylaxis and the Potential Impact of Non- Cyclophosphamide-Exposed T Cells on Outcomes. Biol Blood Marrow Transplant. 2020 Jul 03. PMID: 32629157.
      Citations:    
    7. Braunstein Z, Mishra A, Staub A, Freud AG, Porcu P, Brammer JE. Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response. Br J Haematol. 2020 Jun 09. PMID: 32519348.
      Citations:    
    8. Kartan S, Shalabi D, O'Donnell M, Alpdogan SO, Sahu J, Shi W, Porcu P, Cha J, Nikbakht N. Response to Topical Corticosteroid Monotherapy in Mycosis Fungoides. J Am Acad Dermatol. 2020 May 16. PMID: 32428610.
      Citations:    
    9. Shalabi D, Kartan S, O'Donnell M, Zaya R, Zhan T, Shi W, Alpdogan O, Porcu P, Nikbakht N. Skindex-29 scores indicate poor quality of life in early stage mycosis fungoides. J Dermatol Sci. 2020 Feb 28. PMID: 32362434.
      Citations:    
    10. Haverkos BM, Porcu P. Improved outcomes for extranodal natural killer T-cell lymphoma. Lancet Haematol. 2020 04; 7(4):e272-e273. PMID: 32105607.
      Citations:    
    11. Song A, Gochoco A, Zhan T, Sahu J, Alpdogan O, Porcu P, Nikbakht N, Shi W. A prospective cohort study of Condensed low dose total skin electron beam therapy for mycosis fungoides: reduction of disease burden and improvement in quality of life. J Am Acad Dermatol. 2020 Jan 28. PMID: 32004646.
      Citations:    
    12. Dalvin LA, Lim LS, Ancona-Lezama D, Mazloumi M, Chang M, Porcu P, Martinez NL, Glass J, Mashayekhi A, Shields CL. Clinical Features Predictive of Survival in Patients With Vitreoretinal Lymphoma: Analysis of 70 Patients at a Single Ocular Oncology Center. Asia Pac J Ophthalmol (Phila). 2020 Jan 09. PMID: 31923035.
      Citations:    
    13. Cohen JB, Wei L, Maddocks KJ, Christian B, Heffner LT, Langston AA, Lechowicz MJ, Porcu P, Flowers CR, Devine SM, Blum KA. Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study. Cancer. 2020 03 15; 126(6):1235-1242. PMID: 31821549.
      Citations:    
    14. Vu K, Wu CH, Yang CY, Zhan A, Cavallone E, Berry W, Heeter P, Pincus L, Wieduwilt MJ, William BM, Andreadis C, Kaplan LK, McCormick F, Porcu P, Brammer JE, Ai WZ. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study. Clin Cancer Res. 2019 Nov 26. PMID: 31772119.
      Citations:    
    15. Barta SK, Gong J, Porcu P. Brentuximab vedotin in the treatment of CD30-positive PTCL. Blood. 2019 Oct 25. PMID: 31697814.
      Citations:    
    16. Khodadoust MS, Rook AH, Porcu P, Foss F, Moskowitz AJ, Shustov A, Shanbhag S, Sokol L, Fling SP, Ramchurren N, Pierce R, Davis A, Shine R, Li S, Fong S, Kim J, Yang Y, Blumenschein WM, Yearley JH, Das B, Patidar R, Datta V, Cantu E, McCutcheon JN, Karlovich C, Williams PM, Subrahmanyam PB, Maecker HT, Horwitz SM, Sharon E, Kohrt HE, Cheever MA, Kim YH. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. J Clin Oncol. 2019 Sep 18; JCO1901056. PMID: 31532724.
      Citations:    
    17. Cocks M, Porcu P, Wick MR, Gru AA. Recent Advances in Cutaneous T-cell Lymphoma: Diagnostic and Prognostic Considerations. Surg Pathol Clin. 2019 Sep; 12(3):783-803. PMID: 31352988.
      Citations:    
    18. Bagot M, Porcu P, Marie-Cardine A, Battistella M, William BM, Vermeer M, Whittaker S, Rotolo F, Ram-Wolff C, Khodadoust MS, Bensussan A, Paturel C, Bonnafous C, Sicard H, Azim HA, Kim YH. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2019 Aug; 20(8):1160-1170. PMID: 31253572.
      Citations:    
    19. Sokol K, Kartan S, Johnson WT, Alpdogan O, Nikbakht N, Haverkos BM, Gong J, Porcu P. Extreme Peripheral Blood Plasmacytosis Mimicking Plasma Cell Leukemia as a Presenting Feature of Angioimmunoblastic T-Cell Lymphoma (AITL). Front Oncol. 2019; 9:509. PMID: 31263679.
      Citations:    
    20. Chen J, Pan J, Zhan T, Tuazon S, Saini N, O'Hara W, Filicko-O'Hara J, Klumpp T, Kasner M, Carabasi M, Porcu P, Wagner JL. Autologous Stem Cell Transplantation for Multiple Myeloma: Growth Factor Matters. Biol Blood Marrow Transplant. 2019 Jun 04. PMID: 31173899.
      Citations:    
    21. Johnson W, Mishra A, Binder A, Gru A, Porcu P. Mogamulizumab versus investigator choice in relapsed/refractory adult T-cell leukemia/lymphoma: all four one or none for all? Haematologica. 2019 May; 104(5):864-867. PMID: 31040231.
      Citations:    
    22. Duffy R, Jennings T, Kartan S, Song A, Shi W, Porcu P, Alpdogan O, Sahu J. Special Considerations in the Treatment of Mycosis Fungoides. Am J Clin Dermatol. 2019 Apr 16. PMID: 30993584.
      Citations:    
    23. Kohnken R, McNeil B, Wen J, McConnell K, Grinshpun L, Keiter A, Chen L, William B, Porcu P, Mishra A. Preclinical Targeting of MicroRNA-214 in Cutaneous T-cell Lymphoma (CTCL). J Invest Dermatol. 2019 Mar 12. PMID: 30876800.
      Citations:    
    24. Porcu P, Sahu J, Shi W. Emerging insights on the biology and treatment of cutaneous T-cell lymphoma. Chin Clin Oncol. 2019 Feb; 8(1):1. PMID: 30818956.
      Citations:    
    25. Hossain C, Jennings T, Duffy R, Knoblauch K, Gochoco A, Chervoneva I, Shi W, Alpdogan SO, Porcu P, Pro B, Sahu J. The histological prevalence and clinical implications of folliculotropism and syringotropism in mycosis fungoides. Chin Clin Oncol. 2019 Feb; 8(1):6. PMID: 30818957.
      Citations:    
    26. Alpdogan O, Kartan S, Johnson W, Sokol K, Porcu P. Systemic therapy of cutaneous T-cell lymphoma (CTCL). Chin Clin Oncol. 2019 Feb; 8(1):10. PMID: 30818958.
      Citations:    
    27. Al-Mansour Z, Li H, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Smith SM, Marcellus DC, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Leonard JP, Fisher RI, Friedberg JW, Stiff PJ. Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. Leuk Lymphoma. 2019 Jan 10; 1-8. PMID: 30628511.
      Citations:    
    28. Shalabi D, Bistline A, Alpdogan O, Kartan S, Mishra A, Porcu P, Nikbakht N. Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sézary syndrome (SS). Chin Clin Oncol. 2019 Jan 09. PMID: 30691274.
      Citations:    
    29. Kartan S, Johnson WT, Sokol K, Alpdogan O, Gru AA, Nikbakht N, Porcu P. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin. Chin Clin Oncol. 2019 Jan 09. PMID: 30691273.
      Citations:    
    30. Adams CM, Clark-Garvey S, Porcu P, Eischen CM. Targeting the Bcl-2 Family in B Cell Lymphoma. Front Oncol. 2018; 8:636. PMID: 30671383.
      Citations:    
    31. Oluwasanjo A, Kartan S, Johnson W, Alpdogan O, Gru A, Mishra A, Haverkos BM, Gong J, Porcu P. Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS). Cancer Treat Res. 2019; 176:83-98. PMID: 30596214.
      Citations:    
    32. Jennings T, Duffy R, Gochoco A, Knoblauch K, Shi W, Alpdogan SO, Porcu P, Werner-Wasik M, Sahu J. Valchlor maintenance therapy for patients with mycosis fungoides who received low dose total skin electron beam treatment. Chin Clin Oncol. 2018 Nov 14. PMID: 30525753.
      Citations:    
    33. O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, Kelly V, Flinn I. Duvelisib, an oral dual PI3K-d,? inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. Am J Hematol. 2018 Nov; 93(11):1318-1326. PMID: 30094870.
      Citations:    
    34. Johnson WT, Mukherji R, Kartan S, Nikbakht N, Porcu P, Alpdogan O. Allogeneic hematopoietic stem cell transplantation in advanced stage mycosis fungoides and Sézary syndrome: a concise review. Chin Clin Oncol. 2018 Oct 19. PMID: 30525754.
      Citations:    
    35. Minieri V, De Dominici M, Porazzi P, Mariani SA, Spinelli O, Rambaldi A, Peterson LF, Porcu P, Nevalainen MT, Calabretta B. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia. Cancer Res. 2018 Oct 15; 78(20):5793-5807. PMID: 30154155.
      Citations:    
    36. Mundy-Bosse B, Denlinger N, McLaughlin E, Chakravarti N, Hwang S, Chen L, Mao HC, Kline D, Youssef Y, Kohnken R, Lee DA, Lozanski G, Freud AG, Porcu P, William B, Caligiuri MA, Mishra A. Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma. Blood Adv. 2018 Aug 14; 2(15):1818-1827. PMID: 30054309.
      Citations:    
    37. Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018 Sep; 19(9):1192-1204. PMID: 30100375.
      Citations:    
    38. Kumar A, Vardhana S, Moskowitz AJ, Porcu P, Dogan A, Dubovsky JA, Matasar MJ, Zhang Z, Younes A, Horwitz SM. Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma. Blood Adv. 2018 Apr 24; 2(8):871-876. PMID: 29669753.
      Citations:    
    39. Dugan JP, Haverkos BM, Villagomez L, Martin LK, Lustberg M, Patton J, Martin M, Huang Y, Nuovo G, Yan F, Cavaliere R, Fingeroth J, Kenney SC, Ambinder RF, Lozanski G, Porcu P, Caligiuri MA, Baiocchi RA. Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone. Clin Cancer Res. 2018 Jul 15; 24(14):3273-3281. PMID: 29632007.
      Citations:    
    40. Gru AA, Kim J, Pulitzer M, Guitart J, Battistella M, Wood GS, Cerroni L, Kempf W, Willemze R, Pawade J, Querfeld C, Schaffer A, Pincus L, Tetzlaff M, Duvic M, Scarisbrick J, Porcu P, Mangold AR, Dicaudio DJ, Shinohara M, Hong EK, Horton B, Kim YH. The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome: A Multi-institutional and International Pathology Study. Am J Surg Pathol. 2018 Mar 14. PMID: 29543675.
      Citations:    
    41. Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster JC, Weaver D, Foss FM, Weinstock DM. Activity of the PI3K-d,? inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018 Feb 22; 131(8):888-898. PMID: 29233821.
      Citations:    
    42. Cutucache CE, Porcu P. Editorial: Murine Models of Leukemia and Lymphoma. Front Oncol. 2017; 7:309. PMID: 29376024.
      Citations:    
    43. Flinn IW, O'Brien S, Kahl B, Patel M, Oki Y, Foss FF, Porcu P, Jones J, Burger JA, Jain N, Kelly VM, Allen K, Douglas M, Sweeney J, Kelly P, Horwitz S. Duvelisib, a novel oral dual inhibitor of PI3K-d,?, is clinically active in advanced hematologic malignancies. Blood. 2018 Feb 22; 131(8):877-887. PMID: 29191916.
      Citations:    
    44. Kohnken R, Wen J, Mundy-Bosse B, McConnell K, Keiter A, Grinshpun L, Hartlage A, Yano M, McNeil B, Chakravarti N, William B, Bradner JE, Caligiuri MA, Porcu P, Mishra A. Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma. Blood. 2018 Feb 15; 131(7):771-781. PMID: 29180399.
      Citations:    
    45. Mishra A, Porcu P. Expanding and expounding the genomic map of CTCL. Blood. 2017 09 21; 130(12):1389-1390. PMID: 28935641.
      Citations:    
    46. Porcu P, Sahu J. A positive randomised trial in cutaneous T-cell lymphoma. Lancet. 2017 Jun 06. PMID: 28600131.
      Citations:    
    47. Haverkos BM, Huang Y, Gru A, Pancholi P, Freud AG, Mishra A, Ruppert AS, Baiocchi RA, Porcu P. Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas. Int J Cancer. 2017 04 15; 140(8):1899-1906. PMID: 27943278.
      Citations:    
    48. Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z, Phelps MA, Mortazavi A, Andritsos L, Baiocchi RA, Christian BA, Benson DM, Flynn J, Porcu P, Byrd JC, Pichiorri F, Hofmeister CC. A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leuk Lymphoma. 2017 Oct; 58(10):2310-2318. PMID: 28270022.
      Citations:    
    49. Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017. J Natl Compr Canc Netw. 2017 Mar; 15(3):293-311. PMID: 28275031.
      Citations:    
    50. Haverkos BM, Coleman C, Gru AA, Pan Z, Brammer J, Rochford R, Mishra A, Oakes CC, Baiocchi RA, Freud AG, Porcu P. Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL). Discov Med. 2017 03; 23(126):189-199. PMID: 28472613.
      Citations:    
    51. Kohnken R, Porcu P, Mishra A. Overview of the Use of Murine Models in Leukemia and Lymphoma Research. Front Oncol. 2017; 7:22. PMID: 28265553.
      Citations:    
    52. Virmani P, Hwang SH, Hastings JG, Haverkos BM, Kohnken B, Gru AA, Mishra A, Fabbro SK, Horwitz SM, Porcu P. Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why? Expert Rev Hematol. 2017 Feb; 10(2):111-121. PMID: 27998183.
      Citations:    
    53. Haverkos BM, Pan Z, Gru AA, Freud AG, Rabinovitch R, Xu-Welliver M, Otto B, Barrionuevo C, Baiocchi RA, Rochford R, Porcu P. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases. Curr Hematol Malig Rep. 2016 Dec; 11(6):514-527. PMID: 27778143.
      Citations:    
    54. Kohnken R, Fabbro S, Hastings J, Porcu P, Mishra A. Sézary Syndrome: Clinical and Biological Aspects. Curr Hematol Malig Rep. 2016 12; 11(6):468-479. PMID: 27704468.
      Citations:    
    55. Kohnken R, Kodigepalli KM, Mishra A, Porcu P, Wu L. MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sèzary syndrome patients. Leuk Res. 2017 Jan; 52:58-66. PMID: 27889686.
      Citations:    
    56. Gru AA, Hurley MY, Salavaggione AL, Brodell L, Sheinbein D, Anadkat M, Porcu P, Frater JL. Cutaneous mantle cell lymphoma: a clinicopathologic review of 10 cases. J Cutan Pathol. 2016 Dec; 43(12):1112-1120. PMID: 27539965.
      Citations:    
    57. Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P. NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. J Natl Compr Canc Netw. 2016 Sep; 14(9):1067-79. PMID: 27587620.
      Citations:    
    58. Haverkos BM, Gru AA, Geyer SM, Bingman AK, Hemminger JA, Mishra A, Wong HK, Pancholi P, Freud AG, Caligiuri MA, Baiocchi RA, Porcu P. Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2016 Aug; 16 Suppl:S181-S190.e4. PMID: 27521316; PMCID: PMC4999299.
      Citations:    
    59. Mishra A, La Perle K, Kwiatkowski S, Sullivan LA, Sams GH, Johns J, Curphey DP, Wen J, McConnell K, Qi J, Wong H, Russo G, Zhang J, Marcucci G, Bradner JE, Porcu P, Caligiuri MA. Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. Cancer Discov. 2016 Sep; 6(9):986-1005. PMID: 27422033.
      Citations:    
    60. Freud AG, Keller KA, Scoville SD, Mundy-Bosse BL, Cheng S, Youssef Y, Hughes T, Zhang X, Mo X, Porcu P, Baiocchi RA, Yu J, Carson WE, Caligiuri MA. NKp80 Defines a Critical Step during Human Natural Killer Cell Development. Cell Rep. 2016 Jul 12; 16(2):379-91. PMID: 27373165; PMCID: PMC4970225.
      Citations:    
    61. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Diffuse Large B-Cell Lymphoma Version 1.2016. J Natl Compr Canc Netw. 2016 Feb; 14(2):196-231. PMID: 26850490.
      Citations:    
    62. Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodríguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, Tyler K, Stranzenbach R, Querfeld C, Fava P, Maule M, Willemze R, Evison F, Morris S, Twigger R, Talpur R, Kim J, Ognibene G, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol. 2015 Nov 10; 33(32):3766-73. PMID: 26438120; PMCID: PMC4979132.
      Citations:    
    63. Kiel MJ, Sahasrabuddhe AA, Rolland DC, Velusamy T, Chung F, Schaller M, Bailey NG, Betz BL, Miranda RN, Porcu P, Byrd JC, Medeiros LJ, Kunkel SL, Bahler DW, Lim MS, Elenitoba-Johnson KS. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome. Nat Commun. 2015 09 29; 6:8470. PMID: 26415585; PMCID: PMC4598843.
      Citations:    
    64. Haverkos B, Tyler K, Gru AA, Winardi FK, Frederickson J, Hastings J, Elkins C, Zhang X, Xu-Welliver M, Wong HK, Porcu P. Primary Cutaneous B-Cell Lymphoma: Management and Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of The Ohio State University. Oncologist. 2015 Oct; 20(10):1161-6. PMID: 26306900; PMCID: PMC4591945.
      Citations:    
    65. Kaffenberger B, Haverkos B, Tyler K, Wong HK, Porcu P, Gru AA. Extranodal Marginal Zone Lymphoma-like Presentations of Angioimmunoblastic T-Cell Lymphoma: A T-Cell Lymphoma Masquerading as a B-Cell Lymphoproliferative Disorder. Am J Dermatopathol. 2015 Aug; 37(8):604-13. PMID: 25839892; PMCID: PMC4510028.
      Citations:    
    66. Tyler KH, Haverkos BM, Hastings J, Hu E, Philips R, Gru AA, Welliver MX, Mishra A, Wong HK, Porcu P. The Role of an Integrated Multidisciplinary Clinic in the Management of Patients with Cutaneous Lymphoma. Front Oncol. 2015; 5:136. PMID: 26137450; PMCID: PMC4470273.
      Citations:    
    67. Lustberg ME, Pelletier RP, Porcu P, Martin SI, Quinion CD, Geyer SM, Caligiuri MA, Baiocchi RA. Human leukocyte antigen type and posttransplant lymphoproliferative disorder. Transplantation. 2015 Jun; 99(6):1220-5. PMID: 25427163.
      Citations:    
    68. Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2015 Jun; 169(5):701-10. PMID: 25847298.
      Citations:    
    69. Wong HK, Gibson H, Hake T, Geyer S, Frederickson J, Marcucci G, Caligiuri MA, Porcu P, Mishra A. Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3, GATA6, and TWIST1 in the Sezary Syndrome. J Invest Dermatol. 2015 Aug; 135(8):2084-92. PMID: 25806852.
      Citations:    
    70. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wilson L, Yahalom J, Zafar N, Dwyer M, Sundar H. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Netw. 2015 Mar; 13(3):326-62. PMID: 25736010; PMCID: PMC4841457.
      Citations:    
    71. Majithia L, Rong Y, Siddiqui F, Hattie T, Gupta N, Weldon M, Chakravarti A, Wong HK, Porcu P, Xu-Welliver M. Treating cutaneous T-cell lymphoma with highly irregular surfaces with photon irradiation using rice as tissue compensator. Front Oncol. 2015; 5:49. PMID: 25759793; PMCID: PMC4338671.
      Citations:    
    72. Zhong Y, Dong S, Strattan E, Ren L, Butchar JP, Thornton K, Mishra A, Porcu P, Bradshaw JM, Bisconte A, Owens TD, Verner E, Brameld KA, Funk JO, Hill RJ, Johnson AJ, Dubovsky JA. Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694. J Biol Chem. 2015 Mar 06; 290(10):5960-78. PMID: 25593320; PMCID: PMC4358234.
      Citations:    
    73. Cohen JB, Ruppert AS, Heerema NA, Andritsos LA, Jones JA, Porcu P, Baiocchi R, Christian BA, Byrd JC, Flynn J, Penza S, Devine SM, Blum KA. Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2015 May; 15(5):278-285.e1. PMID: 25660723.
      Citations:    
    74. Hofmeister CC, Williams N, Geyer S, Hade EM, Bowers MA, Earl CT, Vaughn J, Bingman A, Humphries K, Lozanski G, Baiocchi RA, Jaglowski SM, Blum K, Porcu P, Flynn J, Penza S, Benson DM, Andritsos LA, Devine SM. A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. Leuk Lymphoma. 2015 Apr; 56(4):1043-9. PMID: 25213183.
      Citations:    
    75. Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC, Blum KA. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood. 2015 Jan 08; 125(2):242-8. PMID: 25355819.
      Citations:    
    76. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's lymphomas, version 4.2014. J Natl Compr Canc Netw. 2014 Sep; 12(9):1282-303. PMID: 25190696; PMCID: PMC4839265.
      Citations:    
    77. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's lymphomas, version 2.2014. J Natl Compr Canc Netw. 2014 Jun; 12(6):916-46. PMID: 24925202.
      Citations:    
    78. Cohen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA, Hall NC, Nagar VA, Hemminger JA, Jones JA, Porcu P, Christian BA, Baiocchi RA, Maddocks KJ, Flynn JM, Devine SM, Blum KA. Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. Cancer. 2014 Jun 01; 120(11):1677-85. PMID: 24578014; PMCID: PMC4291121.
      Citations:    
    79. Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med. 2013 Oct 31; 369(18):1681-90. PMID: 24171516; PMCID: PMC3985418.
      Citations:    
    80. Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JC. Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma. Am J Hematol. 2014 Jan; 89(1):19-24. PMID: 23959599; PMCID: PMC4150545.
      Citations:    
    81. Kaffenberger BH, Kartono Winardi F, Frederickson J, Porcu P, Wong HK. Periocular cutaneous anaplastic large cell lymphoma clearance with brentuximab vedotin. J Clin Aesthet Dermatol. 2013 Aug; 6(8):29-31. PMID: 24003348; PMCID: PMC3760602.
      Citations:    
    82. de Silva S, Wang F, Hake TS, Porcu P, Wong HK, Wu L. Downregulation of SAMHD1 expression correlates with promoter DNA methylation in Sézary syndrome patients. J Invest Dermatol. 2014 Feb; 134(2):562-565. PMID: 23884314; PMCID: PMC3844041.
      Citations:    
    83. Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M. Non-Hodgkin's lymphomas, version 1.2013. J Natl Compr Canc Netw. 2013 Mar 1; 11(3):257-72; quiz 273. PMID: 23486452.
      Citations:    
    84. Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Naganuma M, Dwyer MA. Non-Hodgkin's Lymphomas, version 3.2012. J Natl Compr Canc Netw. 2012 Dec 1; 10(12):1487-98. PMID: 23221787.
      Citations:    
    85. Mishra A, Liu S, Sams GH, Curphey DP, Santhanam R, Rush LJ, Schaefer D, Falkenberg LG, Sullivan L, Jaroncyk L, Yang X, Fisk H, Wu LC, Hickey C, Chandler JC, Wu YZ, Heerema NA, Chan KK, Perrotti D, Zhang J, Porcu P, Racke FK, Garzon R, Lee RJ, Marcucci G, Caligiuri MA. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell. 2012 Nov 13; 22(5):645-55. PMID: 23153537; PMCID: PMC3627362.
      Citations:    
    86. Gibson HM, Mishra A, Chan DV, Hake TS, Porcu P, Wong HK. Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sézary syndrome. J Invest Dermatol. 2013 Jan; 133(1):249-57. PMID: 22951729; PMCID: PMC4284066.
      Citations:    
    87. Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012 May; 97(5):758-65. PMID: 22133772; PMCID: PMC3342980.
      Citations:    
    88. Mishra A, Porcu P. Early CTCL diagnosis, a (miR)age no more? Blood. 2011 Nov 24; 118(22):5717-8. PMID: 22123905.
      Citations:    
    89. Wong HK, Mishra A, Hake T, Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol. 2011 Oct; 155(2):150-66. PMID: 21883142; PMCID: PMC4309373.
      Citations:    
    90. Querfeld C, Kuzel TM, Kim YH, Porcu P, Duvic M, Musiek A, Rook AH, Mark LA, Pinter-Brown L, Hamid O, Lin B, Bian Y, Boye M, Day JM, Rosen ST. Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leuk Lymphoma. 2011 Aug; 52(8):1474-80. PMID: 21649541.
      Citations:    
    91. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N. Non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2011 May; 9(5):484-560. PMID: 21550968.
      Citations:    
    92. Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X, Johnston JS, Byrd JC, Blum KA. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer. 2011 Jun 01; 117(11):2442-51. PMID: 24048792; PMCID: PMC3116936.
      Citations:    
    93. Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol. 2011 Feb; 64(2):352-404. PMID: 21145619.
      Citations:    
    94. Lessin SR, Porcu P. The state of cutaneous lymphomas: a call to action. Clin Lymphoma Myeloma Leuk. 2010 Sep; 10 Suppl 2:S55-8. PMID: 20826397.
      Citations:    
    95. Porcu P. A look at the National Comprehensive Cancer Network guidelines for cutaneous lymphomas. Clin Lymphoma Myeloma Leuk. 2010 Sep; 10 Suppl 2:S109-11. PMID: 20826394.
      Citations:    
    96. Magro CM, Porcu P, Schaefer J, Erter JW, Furman RR, Shitabata PK, Crowson AN. Cutaneous CD4+ CD56+ hematologic malignancies. J Am Acad Dermatol. 2010 Aug; 63(2):292-308. PMID: 20541283.
      Citations:    
    97. Benson DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, Caligiuri MA. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010 Sep 30; 116(13):2286-94. PMID: 20460501; PMCID: PMC3490105.
      Citations:    
    98. Erter J, Alinari L, Darabi K, Gurcan M, Garzon R, Marcucci G, Bechtel MA, Wong H, Porcu P. New targets of therapy in T-cell lymphomas. Curr Drug Targets. 2010 Apr; 11(4):482-93. PMID: 20196721; PMCID: PMC3953129.
      Citations:    
    99. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Mughal TI, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, Sokol L, Swinnen L, Vose JM, Wierda WG, Yahalom J, Yunus F. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2010 Mar; 8(3):288-334. PMID: 20202462.
      Citations:    
    100. Lin TS, Blum KA, Fischer DB, Mitchell SM, Ruppert AS, Porcu P, Kraut EH, Baiocchi RA, Moran ME, Johnson AJ, Schaaf LJ, Grever MR, Byrd JC. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol. 2010 Jan 20; 28(3):418-23. PMID: 20008633; PMCID: PMC2815704.
      Citations:    
    101. Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC. A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma. 2009 Dec; 50(12):1958-63. PMID: 19860603.
      Citations:    
    102. Porcu P, Wong HK. We should have a dream: unlocking the workings of the genome in cutaneous T-cell lymphomas. Clin Lymphoma Myeloma. 2009 Dec; 9(6):409-11. PMID: 19951878.
      Citations:    
    103. Hamadani M, Benson DM, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine SM. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. Biol Blood Marrow Transplant. 2009 May; 15(5):547-53. PMID: 19361746; PMCID: PMC3953134.
      Citations:    
    104. Blum KA, Hamadani M, Phillips GS, Lozanski G, Johnson AJ, Lucas DM, Smith LL, Baiocchi R, Lin TS, Porcu P, Devine SM, Byrd JC. Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2009 Mar; 50(3):349-56. PMID: 19263294; PMCID: PMC3695225.
      Citations:    
    105. Alinari L, White VL, Earl CT, Ryan TP, Johnston JS, Dalton JT, Ferketich AK, Lai R, Lucas DM, Porcu P, Blum KA, Byrd JC, Baiocchi RA. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. MAbs. 2009 Jan-Feb; 1(1):31-40. PMID: 20046572; PMCID: PMC2715189.
      Citations:    
    106. Katherine Martin L, Porcu P, Baiocchi RA, Erter JW, Chaudhury AR. Primary central nervous system lymphomatoid granulomatosis in a patient receiving azathioprine therapy. Clin Adv Hematol Oncol. 2009 Jan; 7(1):65-8. PMID: 19274043.
      Citations:    
    107. Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Benson DM, Blum KA, Devine SM. Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Leuk Lymphoma. 2008 Oct; 49(10):1893-8. PMID: 18949613.
      Citations:    
    108. Hamadani M, Benson DM, Lin TS, Porcu P, Blum KA, Devine SM. High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Eur J Haematol. 2008 Dec; 81(6):425-31. PMID: 18774954.
      Citations:    
    109. Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F. Non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2008 Apr; 6(4):356-421. PMID: 18433606.
      Citations:    
    110. Alinari L, Geskin L, Grady T, Baiocchi RA, Bechtel MA, Porcu P. Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly. Leuk Res. 2008 Aug; 32(8):1299-303. PMID: 18096224.
      Citations:    
    111. Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, Caligiuri MA, Chan KK, Wu LC, Marcucci G. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood. 2008 Feb 15; 111(4):2364-73. PMID: 18083845; PMCID: PMC2234064.
      Citations:    
    112. Hamadani M, Magro CM, Porcu P. CD4+ CD56+ haematodermic tumour (plasmacytoid dendritic cell neoplasm). Br J Haematol. 2008 Jan; 140(2):122. PMID: 17991297.
      Citations:    
    113. Opavsky R, Tsai SY, Guimond M, Arora A, Opavska J, Becknell B, Kaufmann M, Walton NA, Stephens JA, Fernandez SA, Muthusamy N, Felsher DW, Porcu P, Caligiuri MA, Leone G. Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. Proc Natl Acad Sci U S A. 2007 Sep 25; 104(39):15400-5. PMID: 17881568; PMCID: PMC2000495.
      Citations:    
    114. Czuczman MS, Porcu P, Johnson J, Niedzwiecki D, Kelly M, Hsi ED, Cook JR, Canellos G, Cheson BD. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lymphoma. 2007 Jan; 48(1):97-103. PMID: 17325852.
      Citations:    
    115. Khan KD, Emmanouilides C, Benson DM, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, Caligiuri MA. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res. 2006 Dec 01; 12(23):7046-53. PMID: 17145827.
      Citations:    
    116. Morrison C, Palatini J, Riggenbach J, Radmacher M, Porcu P. Fine-needle aspiration biopsy of non-Hodgkin lymphoma for use in expression microarray analysis. Cancer. 2006 Oct 25; 108(5):311-8. PMID: 16944538.
      Citations:    
    117. Magro CM, Morrison CD, Heerema N, Porcu P, Sroa N, Deng AC. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism. J Am Acad Dermatol. 2006 Sep; 55(3):467-77. PMID: 16908353.
      Citations:    
    118. Magro CM, Seilstad KH, Porcu P, Morrison CD. Primary CD20+CD10+CD8+ T-cell lymphoma of the skin with IgH and TCR beta gene rearrangement. Am J Clin Pathol. 2006 Jul; 126(1):14-22. PMID: 16753590.
      Citations:    
    119. Breza TS, Zheng P, Porcu P, Magro CM. Cutaneous marginal zone B-cell lymphoma in the setting of fluoxetine therapy: a hypothesis regarding pathogenesis based on in vitro suppression of T-cell-proliferative response. J Cutan Pathol. 2006 Jul; 33(7):522-8. PMID: 16872479.
      Citations:    
    120. Zelenetz AD, Advani RH, Buadi F, Cabanillas F, Caligiuri MA, Czuczman MS, Damon LE, Fayad L, Flinn IW, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Kaminski MS, Lacasce AS, Nademanee A, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J. Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Mar; 4(3):258-310. PMID: 16507273.
      Citations:    
    121. Magro CM, Nash JW, Werling RW, Porcu P, Crowson N. Primary cutaneous CD30+ large cell B-cell lymphoma: a series of 10 cases. Appl Immunohistochem Mol Morphol. 2006 Mar; 14(1):7-11. PMID: 16540723.
      Citations:    
    122. Rawal YB, Nuovo GJ, Frambach GE, Porcu P, Baiocchi RA, Magro CM. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. J Cutan Pathol. 2005 Oct; 32(9):616-21. PMID: 16176299.
      Citations:    
    123. Mone A, Puhalla S, Whitman S, Baiocchi RA, Cruz J, Vukosavljevic T, Banks A, Eisenbeis CF, Byrd JC, Caligiuri MA, Porcu P. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia. Blood. 2005 Nov 15; 106(10):3380-2. PMID: 16076875; PMCID: PMC1895052.
      Citations:    
    124. Verma S, Frambach GE, Seilstad KH, Nuovo G, Porcu P, Magro CM. Epstein--Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin. J Cutan Pathol. 2005 Aug; 32(7):474-83. PMID: 16008691.
      Citations:    
    125. Verma S, Nuovo GJ, Porcu P, Baiocchi RA, Crowson AN, Magro CM. Epstein-Barr virus- and human herpesvirus 8-associated primary cutaneous plasmablastic lymphoma in the setting of renal transplantation. J Cutan Pathol. 2005 Jan; 32(1):35-9. PMID: 15660653.
      Citations:    
    126. Porcu P. New approaches to posttransplant lymphoproliferative disorder (PTLD). Clin Adv Hematol Oncol. 2005 Jan; 3(1):24-6. PMID: 16166963.
      Citations:    
    127. Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Stephens J, Byrd JC, Grever MR, Caligiuri MA, Porcu P. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):6101-10. PMID: 15447996.
      Citations:    
    128. Magro C, Crowson AN, Porcu P, Nuovo GJ. Automated kappa and lambda light chain mRNA expression for the assessment of B-cell clonality in cutaneous B-cell infiltrates: its utility and diagnostic application. J Cutan Pathol. 2003 Sep; 30(8):504-11. PMID: 12950502.
      Citations:    
    129. Roychowdhury S, Peng R, Baiocchi RA, Bhatt D, Vourganti S, Grecula J, Gupta N, Eisenbeis CF, Nuovo GJ, Yang W, Schmalbrock P, Ferketich A, Moeschberger M, Porcu P, Barth RF, Caligiuri MA. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res. 2003 Mar 01; 63(5):965-71. PMID: 12615710.
      Citations:    
    130. Porcu P, Eisenbeis CF, Pelletier RP, Davies EA, Baiocchi RA, Roychowdhury S, Vourganti S, Nuovo GJ, Marsh WL, Ferketich AK, Henry ML, Ferguson RM, Caligiuri MA. Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration. Blood. 2002 Oct 01; 100(7):2341-8. PMID: 12239141.
      Citations:    
    131. Marcucci G, Byrd JC, Dai G, Klisovic MI, Kourlas PJ, Young DC, Cataland SR, Fisher DB, Lucas D, Chan KK, Porcu P, Lin ZP, Farag SF, Frankel SR, Zwiebel JA, Kraut EH, Balcerzak SP, Bloomfield CD, Grever MR, Caligiuri MA. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood. 2003 Jan 15; 101(2):425-32. PMID: 12393493.
      Citations:    
    132. Porcu P, Farag S, Marcucci G, Cataland SR, Kennedy MS, Bissell M. Leukocytoreduction for acute leukemia. Ther Apher. 2002 Feb; 6(1):15-23. PMID: 11886572.
      Citations:    
    133. Shah MH, Porcu P, Mallery SR, Caligiuri MA. AIDS-associated malignancies. Cancer Chemother Biol Response Modif. 2002; 20:633-64. PMID: 12703228.
      Citations:    
    Porcu's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (379)
    Explore
    _
    Co-Authors (31)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _